OCULAR THERAPEUTIX INC (OCUL)
US67576A1007 - Common Stock
OCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024
OCUL stock results show that Ocular Therapeutix missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
OCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocular Therapeutix (NASDAQ:OCUL) just reported results for the first quarter of...
Ocular Therapeutix™ Reports First Quarter 2024 Results
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing...
Top movers in Monday's pre-market session
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed...
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
2024 OIS Retina and ARVO meetings are being held in Seattle, Washington...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call;...
OCUL Makes Notable Cross Below Critical Moving Average
2 Small-Cap Growth Stocks With Room To Run
These two small-cap growth stocks could be ready to run.
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0%...
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
Ocular Therapeutix Becomes Oversold (OCUL)
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing...
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with...
Million-Dollar Bets: 3 Under-$15 Stocks With Massive Potential
Here are three under-$15 stocks with massive potential based on their strategic moves in the pharmaceuticals and banking industries.
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed...
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, the “Company”), a biopharmaceutical company committed to...
3 Stocks to Buy That Are Up 100% or More in 2024
While stocks up 100% don’t seem like a particularly great deal, these high-flying entities can still provide more rewards.